


The Sky is the Limit

Motivation to treatment with extended-release naltrexone


Zhanna Gaulen, M.Phil

PhD candidate, Medical faculty, University of Bergen
Department of Addiction Medicine, Haukeland University Hospital

Extended-release naltrexone = VIVITROL®



Extended-release naltrexone = VIVITROL®






THERE WAS NO CONFLICT OF INTEREST


Extended-release naltrexone = VIVITROL®

Inclusion criteria

- 18 years or older
- in medically assisted rehabilitation
- not actively psychotic or suicidal
- no organ failure
- not pregnant or breastfeeding



TIMELINE



Extended-release naltrexone

RCT



12 weeks



FOLLOW-UP



36 weeks



MAIN OBJECTIVES

Initial treatment motivation level



adherence to treatment



first relapse



use of heroin and other illicit opioids




METHODS



Questionnaire on interest in a new treatment

0	1	2	3	4
Not interested	Little interest	Some interest	Quite interested	Very interested

Spørsmål om heroinblokkerende behandling  Seraf
Sentral for rus- og avhengighetsforskning

Sted: _____ Dato: _____ Initialer: _____ Fødselsdato: _____ Utprøver(sign): _____

INSTRUKS: Vennligst les følgende utsagn nøye. Nedenfor står ulike utsagn om bruk av heroin og andre opiatet og muligheten for behandling av dette med naltrekson. Naltrekson er et opiatblokkerende legemiddel som kan gis som langtidsvirkende depot, er uten misbruks- eller ruspotensiale.

For hvert utsagn 1-8, sett en sirkel rundt et nummer fra 0 til 4 for å vise din interesse for det som utsagnet beskriver. Sett bare ring rundt ett svar for hvert utsagn.

Hvor interessert er du nå i å...	0 Ikke inter- essert	1 Litt inter- essert	2 Noe inter- essert	3 Gan- ske inter- essert	4 Svært inter- essert
1. Slutte med all bruk av heroin eller andre opiatet i en 4-ukers periode eller flere 4-ukers perioder.	0	1	2	3	4
2. Slippe å bruke LAR-medikamenter for å redusere heroinbruken	0	1	2	3	4
3. Motta et legemiddel som gir meg mindre lyst på de fleste rusmidler.	0	1	2	3	4
4. Motta et legemiddel som blokkerer virkningen av heroin i 4 uker av gangen etter gjennomført avrusing/ nedtrapping av opiatet.	0	1	2	3	4
5. Motta en injeksjon i setemuskel med et legemiddel som blokkerer virkningen av heroin i 4 uker hver gang.	0	1	2	3	4
6. Få tilbud om denne typen behandling et år frem i tid.	0	1	2	3	4
7. I nær fremtid delta i et forskningsprosjekt der denne typen behandling prøves ut.	0	1	2	3	4
8. Få mer informasjon om denne typen behandling.	0	1	2	3	4

9. Hvis jeg kunne velge mellom å motta behandling i vanlig LAR eller få heroinblokkerende medisin fra neste uke, ville jeg valgt:

LAR Blokkerende behandling med 4 ukers varighet på blokkaden

10. Kryss av her om du ønsker å bli kontaktet for informasjon om å delta i et forskningsprosjekt på heroinblokkerende behandling


Skjemaet sendes - eller leveres tilbake etter utfylling. Utfyllt skjema blir behandlet konfidensielt.

MacBook

METHODS




**Questionnaire on interest
in a new treatment**



Motivation levels:

- High
- Medium
- Low



METHODS



**Questionnaire on interest
in a new treatment**



EuropASI



**Cox regression
Linear mixed models**

**Motivation
to treatment
&**

- drop-out
- relapse
- illicit opioid use

MacBook

DESCRIPTIVE RESULTS




● **Included in RCT: 159**
Completed 105

● **Included in FU: 117**
Completed: 58

Lifetime characteristics	XR-NTX	BP-NLX
Age	36	36
Men	61%	51%
Women	19%	25%
Heroin use	7 y.	7 y.

Motivation level and outcomes



Follow-up period


MOTIVATION to XR-NTX treatment

High



The Sky is the Limit

Medium



Continued group

First relapse

Low



Continued group
Switched group
Both groups

First relapse
Opioid use
Drop-out



PUBLICATIONS

Interest in Extended Release Naltrexone among Opioid Users

Kamni Sharma Haase^{a,b} Nikolaj Kunøe^a Arild Opheim^c Zhanna Gaulen^c
Ann-Lill Mjølhus Njå^d Zill-E-Huma Latif^e Kristin Klemmetsby Solli^a
Lars Tanum^{a,e}

JAMA Psychiatry | Original Investigation

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial

Lars Tanum, MD, DMSci; Kristin Klemmetsby Solli, MSc; Zill-e-Huma Latif, MD; Jüratė Šaltytė Benth, PhD; Arild Opheim, MSc; Kamni Sharma-Haase, MD; Peter Krajci, MD, PhD; Nikolaj Kunøe, MSc, PhD

JAMA Psychiatry | Original Investigation

Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study

Zill-e-Huma Latif, MD; Jüratė Šaltytė Benth, MSc, PhD; Kristin Klemmetsby Solli, MSc, PhD; Arild Opheim, MSc; Nikolaj Kunøe, MSc, PhD; Peter Krajci, MD, PhD; Kamni Sharma-Haase, MD; Lars Tanum, MD, PhD

European
Addiction
Research

Research Article

Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial

Solli K.K.^{a,b,c} · Kunøe N.^a · Latif Z.-E.-H.^b · Sharma-Haase K.^c · Opheim A.^{d,e} · Krajci P.^f · Gaulen Z.^{d,e} · Šaltytė Benth J.^{g,h} · Tanum L.^{b,i}

Eur Addict Res
DOI: 10.1159/000447964

Kunøe et al. *BMC Pharmacology and Toxicology* (2016) 17:18
DOI 10.1186/s10360-016-0061-1

BMC Pharmacology
and Toxicology

STUDY PROTOCOL

Open Access



2016

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)

Nikolaj Kunøe^{1*}, Arild Opheim^{3,4}, Kristin Klemmetsby Solli¹, Zhanna Gaulen^{3,4}, Kamni Sharma-Haase^{1,5}, Zill-e-Huma Latif^{1,2} and Lars Tanum^{1,2}

ADDICTION

SSA SOCIETY FOR THE
STUDY OF
ADDICTION

RESEARCH REPORT

doi:10.1111/add.1427

2017

Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial

Kristin Klemmetsby Solli¹ , Zill-e-Huma Latif² , Arild Opheim^{3,4}, Peter Krajci⁵, Kamni Sharma-Haase^{1,6}, Jüratė Šaltytė Benth^{7,8}, Lars Tanum^{2,1*} & Nikolaj Kunøe^{1*}

The American Journal on Addictions, XX: 1–9, 2019
© 2019 American Academy of Addiction Psychiatry
ISSN: 1055-0496 print / 1521-0391 online
DOI: 10.1111/ajad.12859

2018

No Increased Pain Among Opioid-Dependent Individuals Treated with Extended-Release Naltrexone or Buprenorphine-Naloxone: A 3-Month Randomized Study and 9-Month Open-Treatment Follow-Up Study

Zill-e-Huma Latif, MD,¹ Kristin K. Solli, MSc, PhD,^{1,2} Arild Opheim, MSc,^{3,4} Nikolaj Kunøe, MSc, PhD,² Jüratė S. Benth, MSc, PhD,^{5,6} Peter Krajci, MD, PhD,⁷ Kamni Sharma-Haase, MD,² Lars Tanum, MD, PhD^{1,2}

2019

Thank you for your attention

Acknowledgements

- **Lars Tanum**, Senior Researcher, Norwegian Centre for Addiction Research at the University of Oslo
- **Lars Thore Fadnes**, Associate Professor, Department of Global Public Health and Primary Care, University of Bergen
- **Department of Addiction Medicine**, Haukeland University Hospital
- **Faculty of Medicine**, University of Bergen

Contact



zhanna.gaulen@helse-bergen.no



+47 416 35 221